uric acid has been researched along with linagliptin in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ishibashi, Y; Matsui, T; Ojima, A; Sugiura, T; Yamagishi, S | 1 |
1 other study(ies) available for uric acid and linagliptin
Article | Year |
---|---|
Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor, decreases serum uric acid levels in type 2 diabetic patients partly by suppressing xanthine oxidase activity.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Hypoglycemic Agents; Linagliptin; Male; Middle Aged; Prospective Studies; Purines; Quinazolines; Uric Acid; Xanthine Oxidase | 2014 |